Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Authors	Daria V Babushok, Ernest J Nelson, Jennifer J D Morrissette, Shivam Joshi, Matthew B Palmer, Dale Frank, Carolyn L Cambor, Elizabeth O Hexner
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 60 Issue 3 Pg. 852-855 (03 2019) ISSN: 1029-2403 [Electronic] United States
PMID	30227762 (Publication Type: Letter, Research Support, N.I.H., Extramural)
Chemical References	Janus Kinase Inhibitors Nitriles Pyrazoles Pyrimidines ruxolitinib Janus Kinase 2
Topics	Amyloidosis (diagnosis, etiology) Hematologic Neoplasms (etiology) Humans Janus Kinase 2 (antagonists & inhibitors, genetics) Janus Kinase Inhibitors (adverse effects, therapeutic use) Kidney Diseases (diagnosis, etiology) Male Middle Aged Nitriles Primary Myelofibrosis (complications, drug therapy, genetics) Pyrazoles (adverse effects, therapeutic use) Pyrimidines Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!